Dale, D. C., Firkin, F., Bolyard, A. A., Kelley, M., Makaryan, V., Gorelick, K. J., . . . Beaussant Cohen, S. (2020). Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood.
Dyfyniad Arddull ChicagoDale, David C., et al. "Results of a Phase 2 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of WHIM Syndrome." Blood 2020.
Dyfyniad MLADale, David C., et al. "Results of a Phase 2 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of WHIM Syndrome." Blood 2020.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.